Pfizer (NYSE: PFE) has announced interim results from a Phase III trial evaluating its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18 to 59 at risk of severe RSV-associated lower respiratory tract disease (LRTD). Currently, the vaccine is approved for preventing RSV-associated LRTD in older adults and for maternal immunization of unborn infants.
The company reported that the trial met its primary endpoints for immunogenicity and safety. Early data indicate that neutralizing responses were non-inferior to those seen in individuals aged 60 and above, and the vaccine demonstrated a favorable safety profile.
These promising results could position Abrysvo as the first RSV immunization approved for younger adults.- Flcube.com
